Scarica l'app Stockscreener
26.53
2.43%
-0.66
Dopo l'orario di chiusura:
26.53
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALKS Giù?
Forum
Previsione
Frazionamento azionario
Alkermes Plc Borsa (ALKS) Ultime notizie
What drives Alkermes plc stock priceUnprecedented growth rates - Autocar Professional
Alkermes plc (NASDAQ:ALKS) Launches Phase II Trial of ALKS 2680 for Idiopathic Hypersomnia - MSN
Abivax’s miRNA therapy emerges as a new mechanism for ulcerative colitis - BioCentury
Goldman Sachs Initiates Alkermes (ALKS) with a Buy Rating - MSN
What analysts say about Alkermes plc stockHigh-yield portfolio picks - Autocar Professional
Alkermes plc Stock Analysis and ForecastSuperior investment outcomes - jammulinksnews.com
Is Alkermes plc a good long term investmentFree Wealth Planning Blueprint - jammulinksnews.com
Alkermes (ALKS) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
ALKS Down Despite Positive Top-Line Data From Narcolepsy Study - TradingView
Alkermes Announces Positive Phase 2 Study Results - TipRanks
Alkermes To Advance Alixorexton After Positive Phase II Narcolepsy Results - insights.citeline.com
Jefferies Raises Target for Alkermes (ALKS) Following Promising Drug Data | ALKS Stock News - GuruFocus
Alkermes Offers The Next Proof Point For Its Narcolepsy Approach. Stock Dives. - inkl
Alkermes Oral Drug Helps Patients Stay Awake In Mid-Stage Sleep Disorder Study - inkl
Alkermes narcolepsy drug headed for late-stage testing - BioPharma Dive
Needham & Company LLC Reaffirms Buy Rating for Alkermes (NASDAQ:ALKS) - MarketBeat
Alkermes stock rating reiterated as Buy by Stifel after positive narcolepsy data - Investing.com UK
Alkermes Vibrance-1 Phase 2 Study Of Alixorexton In Narcolepsy Type 1 Meets Primary Goal - Nasdaq
Alkermes announces positive topline results from Vibrance-1 Phase 2 study - MarketScreener
Alkermes narcolepsy drug shows positive results in phase 2 trial By Investing.com - Investing.com UK
Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1 - PR Newswire
Alkermes Orexin Receptor Agonist Shows Broad Benefits in Phase 2 Narcolepsy Study - Sleep Review
Is Alkermes Plc's (NASDAQ:ALKS) Latest Stock Performance Being Led By Its Strong Fundamentals? - 富途牛牛
10 Most Undervalued Pharma Stocks To Buy Now - Insider Monkey
BlackRock increases stake in Alkermes to 17.05% By Investing.com - Investing.com India
BlackRock increases stake in Alkermes to 17.05% - Investing.com
Alkermes to Release Q2 Financial Results on July 29, 2025 - AInvest
Alkermes to Report Second Quarter Financial Results on July 29, 2025 - MarketScreener
Expert Outlook: Alkermes Through The Eyes Of 6 Analysts - Benzinga
Goldman Sachs Initiates Coverage on Alkermes (ALKS) with a Buy R - GuruFocus
How Much Upside is Left in Alkermes (ALKS)? Wall Street Analysts Think 33.19% - Yahoo Finance
(ALKS) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Alkermes (NASDAQ:ALKS) shareholders have earned a 9.3% CAGR over the last five years - simplywall.st
3.25%
0.75%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):